Literature DB >> 33467550

Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.

Elanora Dovat1, Chunhua Song1,2, Tommy Hu1, Mohammad Atiqur Rahman1, Pavan Kumar Dhanyamraju1, Morgann Klink1, Daniel Bogush1, Mario Soliman1, Shriya Kane1, Mary McGrath1, Yali Ding1, Dhimant Desai3, Arati Sharma3, Chandrika Gowda1.   

Abstract

IKAROS, encoded by the IKZF1 gene, is a DNA-binding protein that functions as a tumor suppressor in T cell acute lymphoblastic leukemia (T-ALL). Recent studies have identified IKAROS's novel function in the epigenetic regulation of gene expression in T-ALL and uncovered many genes that are likely to be directly regulated by IKAROS. Here, we report the transcriptional regulation of two genes, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (PIK3CD) and phosphoinositide kinase, FYVE-type zinc finger containing (PIKFYVE), by IKAROS in T-ALL. PIK3CD encodes the protein p110δ subunit of phosphoinositide 3-kinase (PI3K). The PI3K/AKT pathway is frequently dysregulated in cancers, including T-ALL. IKAROS binds to the promoter regions of PIK3CD and PIKFYVE and reduces their transcription in primary T-ALL. Functional analysis demonstrates that IKAROS functions as a transcriptional repressor of both PIK3CD and PIKFYVE. Protein kinase CK2 (CK2) is a pro-oncogenic kinase that is overexpressed in T-ALL. CK2 phosphorylates IKAROS, impairs IKAROS's DNA-binding ability, and functions as a repressor of PIK3CD and PIKFYVE. CK2 inhibition results in increased IKAROS binding to the promoters of PIK3CD and PIKFYVE and the transcriptional repression of both these genes. Overall, the presented data demonstrate for the first time that in T-ALL, CK2 hyperactivity contributes to PI3K signaling pathway upregulation, at least in part, through impaired IKAROS transcriptional regulation of PIK3CD and PIKFYVE. Targeting CK2 restores IKAROS's regulatory effects on the PI3K oncogenic signaling pathway.

Entities:  

Keywords:  IKAROS; PI3K; T cell acute lymphoblastic leukemia; protein kinase CK2; transcriptional regulation

Mesh:

Substances:

Year:  2021        PMID: 33467550      PMCID: PMC7830534          DOI: 10.3390/ijms22020819

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  45 in total

Review 1.  Ikaros chromatin remodeling complexes in the control of differentiation of the hemo-lymphoid system.

Authors:  J Koipally; J Kim; B Jones; A Jackson; N Avitahl; S Winandy; M Trevisan; A Nichogiannopoulou; C Kelley; K Georgopoulos
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1999

Review 2.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

Review 3.  Ikaros, CK2 kinase, and the road to leukemia.

Authors:  Sinisa Dovat; Chunhua Song; Kimberly J Payne; Zhanjun Li
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

Review 4.  Ikaros and acute leukemia.

Authors:  Charles Mullighan; James Downing
Journal:  Leuk Lymphoma       Date:  2008-05

5.  CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.

Authors:  Haiwei Lian; Dun Li; Yun Zhou; Esther Landesman-Bollag; Guanglan Zhang; Nicole M Anderson; Kevin Charles Tang; Justine E Roderick; Michelle A Kelliher; David C Seldin; Hui Fu; Hui Feng
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

6.  Role of Ikaros in T-cell acute lymphoblastic leukemia.

Authors:  Philippe Kastner; Susan Chan
Journal:  World J Biol Chem       Date:  2011-06-26

7.  Tumor suppression in T cell leukemia--the role of Ikaros.

Authors:  Sinisa Dovat; Kimberly J Payne
Journal:  Leuk Res       Date:  2009-11-04       Impact factor: 3.156

Review 8.  Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.

Authors:  Chandrika Gowda; Mansi Sachdev; Sunil Muthusami; Malika Kapadia; Lidija Petrovic-Dovat; Melanie Hartman; Yali Ding; Chunhua Song; Jonathon L Payne; Bi-Hua Tan; Sinisa Dovat
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

9.  Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.

Authors:  C Song; X Pan; Z Ge; C Gowda; Y Ding; H Li; Z Li; G Yochum; M Muschen; Q Li; K J Payne; S Dovat
Journal:  Leukemia       Date:  2015-12-07       Impact factor: 11.528

Review 10.  Targeting PI3K Signaling in Acute Lymphoblastic Leukemia.

Authors:  Vanessa Edna Sanchez; Cydney Nichols; Hye Na Kim; Eun Ji Gang; Yong-Mi Kim
Journal:  Int J Mol Sci       Date:  2019-01-18       Impact factor: 5.923

View more
  4 in total

Review 1.  The Role of Protein Kinase CK2 in Development and Disease Progression: A Critical Review.

Authors:  Daniel Halloran; Venu Pandit; Anja Nohe
Journal:  J Dev Biol       Date:  2022-07-27

Review 2.  Protein kinase CK2 - diverse roles in cancer cell biology and therapeutic promise.

Authors:  Janeen H Trembley; Betsy T Kren; Muhammad Afzal; George A Scaria; Mark A Klein; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2022-09-17       Impact factor: 3.842

3.  Reversal of IKZF1-induced glucocorticoid resistance by dual targeting of AKT and ERK signaling pathways.

Authors:  Miriam Butler; Britt M T Vervoort; Dorette S van Ingen Schenau; Lieneke Jongeneel; Jordy C G van der Zwet; René Marke; Jules P P Meijerink; Blanca Scheijen; Laurens T van der Meer; Frank N van Leeuwen
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

4.  Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.

Authors:  Zhiyong Li; Yang Liu; Huijie Yi; Ting Cai; Yunwei Wei
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.